AMBU B Ambu A/S Class B

AMBU ANNOUNCES PRELIMINARY FINANCIAL RESULTS FOR THE FISCAL YEAR 2022/23

AMBU ANNOUNCES PRELIMINARY FINANCIAL RESULTS FOR THE FISCAL YEAR 2022/23

Today, Ambu announces its preliminary financial 2022/23 results. For the financial year 2022/23, EBIT before special items totalled DKK 302m, with an EBIT margin before special items of 6.3% (previous outlook: 5 – 6%), mainly driven by scale in OPEX and product mix.



PRELIMINARY FINANCIAL HIGHLIGHTS FOR THE FULL FINANCIAL YEAR 2022/23

Last year’s comparative figures are stated in brackets.

  • Revenue was DKK 4,775m (DKK 4,444m), with organic growth of 7.6% (4%), driven by strong growth in Endoscopy Solutions. Reported growth for the year was 7.4% (11%). 
  • Gross margin was 56.8% (57.5%), mainly impacted by a strengthened product mix, driven by Endoscopy Solutions.
  • EBIT before special items was DKK 302m (DKK 122m), corresponding to a margin of 6.3% (2.7%), mainly driven by scale in OPEX.



Based on the preliminary full-year 2023/23 results, Ambu’s organic revenue growth and EBIT margin before special items are as follows:

 Previous outlook9 October 2023
Organic revenue growth6 - 8%7.6%
EBIT margin before special items5 - 6%6.3%



The stated preliminary results for the full financial year 2022/23 are unaudited.

Ambu will release its Annual Report on 8 November 2023.







Ambu A/S

Baltorpbakken 13 2750 Ballerup 

Denmark

Tel.  

CVR no.: 63 64 49 19





CONTACT



Investors 

Anders Hjort 

Head of Investor Relations

 

Media 

Tine Bjørn Schmidt

Head of Corporate Communications







ABOUT AMBU

Since 1937, Ambu has been rethinking solutions, together with healthcare professionals, to save lives and improve patient care. Today, millions of patients and healthcare professionals worldwide depend on the efficiency, safety and performance of our single-use endoscopy, anaesthesia and patient monitoring solutions. Headquartered near Copenhagen in Denmark, Ambu employs around 4,500 people in Europe, North America, Latin America and Asia Pacific. For more information, please visit Ambu.com.



Attachment



EN
09/10/2023

Underlying

AMBU BAmbu A/S Class B

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ambu A/S Class B

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
AMBU B Ambu A/S Class ...

Flattening revenues AND bulky valuation

Q2 largely inline with pre-announcement. Q2 was the peak for growth, H2 revenues flattening out. At 71x P/E Ambu needs time to grow into its bulky valuation.

AMBU B AMBU A/S CLASS B
05/15/24 May 15, 2024 1 EN
Jesper Ingildsen
  • Jesper Ingildsen
Free Trial
AMBU B Ambu A/S Class ...

Ambu (Buy, TP: DKK138.00) - Guidance still looks conservative

Having pre-released Q2 headline numbers and increased the 2024 guidance in mid-April, today’s detailed results provided few surprises. However, the important Endoscopy sales were slightly better than expected, and we find today’s guidance for >15% organic growth YOY (previously c15%) for that part of company still conservative, with potential for a further rise with the Q3 results. We reiterate our BUY and have increased our target price to DKK138 (130).

AMBU B AMBU A/S CLASS B
05/14/24 May 14, 2024 1 EN
Free Trial
AMBU B Ambu A/S Class ...

Ambu AS: 1 director

A director at Ambu AS bought 12,500 shares at 118.560DKK and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...

AMBU B AMBU A/S CLASS B
02/09/24 February 9, 2024 1 EN
 PRESS RELEASE
Free
AMBU B Ambu A/S Class ...

Ambu A/S: Reporting of transactions made by persons discharging manage...

Ambu A/S: Reporting of transactions made by persons discharging managerial responsibilities Pursuant to the Market Abuse Regulation, article 19, Ambu A/S hereby notifies receipt of information of the following transaction(s) made by persons discharging managerial responsibilities in Ambu A/S and/or their closely associated persons related to Ambu A/S’s shares admitted to trading and official listing on Nasdaq Copenhagen A/S.   The attached document discloses the data of the transactions made in Ambu shares.  Attachment

February 9, 2024 1 EN
 PRESS RELEASE
Free
AMBU B Ambu A/S Class ...

GRANT OF PERFORMANCE SHARE UNITS

GRANT OF PERFORMANCE SHARE UNITS Pursuant to Ambu A/S’ (Ambu) Remuneration Policy, a total of 172,956 Performance Share Units (PSUs) related to Ambu’s long-term incentive programme (LTIP) for 2023/24 have been granted on 6 February 2024 with retroactive effect from 1 January 2024. 49,109 of the PSUs have been granted to the Executive Management and 123,847 of the PSUs have been granted to other key employees.  The LTIP covers the financial year 2023/24, and the final allocation of PSUs is conditional upon achievement of two key performance indicators (organic revenue growth and EBIT marg...

February 6, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch